rezatapopt (** Generic name only (investigational); no commercial brand names yet established. **)

Description

Rezatapopt is an experimental (investigational) oral medication currently being studied in clinical trials for certain advanced cancers. It is being investigated as a potential treatment for colorectal cancer patients whose tumors have a specific mutation in the TP53 gene, known as the Y220C mutation. This mutation is found in a small percentage of colorectal cancers. Rezatapopt belongs to a class of drugs called p53 reactivators. It is being studied both on its own (monotherapy) and in combination with other cancer drugs like pembrolizumab (an immunotherapy drug). The goal of these trials is to determine the right dose, how safe it is, and if it can shrink tumors or slow their growth in patients with this specific TP53 mutation. It is not yet approved for use in colorectal cancer or any other cancer.

Mechanism of Action

Rezatapopt is designed to target and 'reactivate' the p53 protein within cancer cells. The p53 protein is often called the 'guardian of the genome' because it helps control cell growth and can trigger cell death (apoptosis) if DNA damage is detected. However, certain mutations, like the TP53 Y220C mutation, can prevent the p53 protein from working correctly. Rezatapopt is specifically designed to bind to and restore the function of the p53 protein when this particular Y220C mutation is present, potentially helping the cancer cell self-destruct or become more sensitive to other treatments.

Side Effects

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials